John Valliant, Chief Executive Officer at Fusion Pharmaceuticals Inc. (FUSN), sold 80,704 shares at $7.99 ($649K) on 2022-02-16, disclosed to the SEC on 2022-02-17.
Open-market sale of $649k FUSN by Chief Executive Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.33 | 12,600 | $105K | 16.2% |
| 2 | $7.99 | 33,202 | $265K | 40.9% |
| 3 | $7.99 | 33,202 | $265K | 40.9% |
| 4 | $7.98 | 1,700 | $14K | 2.1% |
| Total | $8.04 avg | 80,704 | $649K | 100% |
| Filing → |
| FUSN | SELL | 2022-04-13 | $432K | — | Filing → |
| FUSN | SELL | 2022-04-08 | $16K | — | Filing → |
| FUSN | SELL | 2022-04-05 | $29K | — | Filing → |